-
Trastuzumab and Pertuzumab from QILU PHARMACEUTICAL: A Promising and Reliable Therapeutic Option for Patients with HER2-Positive Breast Cancer
Oncology Frontier has distilled key insights from this symposium, offering a comprehensive and detailed overview of the latest advancements in the management of HER2-positive breast cancer. Advancing Neoadjuvant Therapy for…
-
SGBCC 2025丨Dr. Giuseppe Curigliano: Cure Outlook for Advanced Breast Cancer Patients — Innovative Therapies and Treatment Challenges
From March 12 to 15, 2025, the 19th St. Gallen Breast Cancer Conference (SGBCC 2025) was held in Vienna, the capital of music. Experts from around the world in the field of breast cancer gathered to discuss cutting-edge advancements and hotly debated topics in breast cancer diagnosis and treatment. Oncology Frontier invited Dr. Giuseppe Curigliano,…
-
JOH | FFAR1/FFAR4 Agonists Show Promise in MASH Treatment
The ICONA trial was a multicenter, randomized, double-blind, placebo-controlled Phase IIb study that enrolled 280 patients with MASH between the ages of 18 and 75. Participants were randomly assigned to…
-
NHHR Shows Great Potential in Predicting MASLD in Obese and Type 2 Diabetes Populations
Non-high-density lipoprotein cholesterol (Non-HDL-C) is calculated by subtracting high-density lipoprotein cholesterol (HDL-C) from total cholesterol (TC). The ratio of Non-HDL-C to HDL-C (NHHR) is an emerging composite lipid marker. Previous…
-
Introducing the Val d’Isère – Vilgrain Radiology Congress 2025!
Exciting news for the radiology community! Professor Valérie Vilgrain is organizing the inaugural Val d’Isère – Vilgrain Radiology Congress, set to take place from March 24-28, 2025, in the stunning…
-
Dr. Xuefeng Luo: Precision Reduction of Portal Pressure to Balance Ascites Control and Hepatic Encephalopathy Risk After TIPS
Background: The Clinical Dilemma of TIPS – A Double-Edged Sword in Cirrhosis Treatment Cirrhosis is a major global health burden, causing approximately 170,000 deaths annually in Europe alone (Pimpin L,…
-
New Study on ATM, CHEK2, and PALB2 Variants: No Significant Impact on Cancer Mortality
A recent study published in the Journal of Clinical Oncology provides important insights into the prognostic role of pathogenic variants (PVs) in ATM, CHEK2, and PALB2 in breast, colorectal, and…
Connecting Medical Expertise through Media
